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exacerbation, lung function, TCM symptom score, exercise capacity, and quality of life will be assessed.
Discussion
It is hypothesized that SHGBZK will have beneficial effects in reducing the frequency and duration of acute exacerbation, improving exercise capacity function of COPD patients at stable stage that diagnosed with syndrome of deficiency of lung qi and spleen qi. This study may establish a new method for COPD patients, and thus differentiation from other drugs used for similar clinical indications in clinical use.
Background COPD is characterized by persistent and limited airflow, which can be progressively aggravated. The repeated acute exacerbation of COPD AECOPD can lead to a variety of complications, which cause the overall situation of disease getting worse [1] . Its reductions are a major goal of COPD management and an important indicator for evaluating the treatments. According to statistics, [2]the incidence of COPD is about 10% in the global population. It is expected that the fatality rate of COPD will rise to the third place in the world [3] , and the economic burden will rank the fifth in the world by 2020. In China, the prevalence of COPD in people over 40 years old is 8.2% [4] , the number of deaths due to COPD exceeds 1 million each year, and the number of disabled people over 5 million. In addition to pulmonary symptoms, studies [5] have shown that the most common complications of COPD patients are cardiovascular disease, diabetes, asthma and anemia. Most patients have one or two complications, which increase the social and economic burden. And most patients have mental anxiety symptoms [6] , which affects the working ability and quality of life [7] of patients seriously. As COPD can be prevented, effective preventive measures will help to delay the recurrence and progressive aggravation of the disease.
Current treatments for COPD include inhaled corticosteroids and bronchodilators [8] .
Although effective at alleviating symptoms, these treatment methods do not alter disease progression. There is a pressing need searching a better treatment [9] , which could have a certain effect in improving the clinical symptoms, lower lung function decline, reduce mortality and shorten the hospitalization time. Traditional Chinese medicine has a great advantage in reducing the risk for severe exacerbation, improving lung function, positively impacting quality of life, and improving exercise capacity in stabilized patients with COPD, which can supplement the deficiency of modern medical treatment [10] .
SHGBZK Chinese medicine is a Chinese herbal formula developed by Professor Chao
Enxiang, a great doctor of Chinese medicine, who has more than 50 years of clinical experience. Preliminary clinical data demonstrated that it has good clinical efficacy in COPD and no obvious side effects [11] . Animal experiments have enhanced that it has mucosal immune barrier function, it can maintain airway wall integrity, reduce inflammatory cell infiltration, promote inflammatory damage repair, and relieve airway narrow conditions [12] . This study aims to evaluate the efficacy and safety of SHGBZK Chinese medicine for further research, in order to form a new safe and effective method in the treatment of stable COPD.
Study objectives: This study will evaluate the safety and efficacy of the Chinese herbal formula SHGBZK Chinese medicine as a treatment for COPD patients at stable stage that diagnosed with syndrome of deficiency of lung qi and spleen qi.
Design and Setting: One hundred patients with stable COPD were randomly assigned to two treatment groups SHGBZK Chinese medicine treatment, N=50; placebo treatment, N=50 . The two groups will receive basic treatment for COPD according to the 2017 GOLD Guidelines for Chronic Obstructive Pulmonary Disease. Both groups will receive an 24-weeks intervention, and patient status was assessed at 24 weeks later and 28 weeks after treatment. 
Methods

Study design
We will conduct a A randomized, double-blind, placebo-controlled trial. A flowchart of the study protocol is shown in Figure 1 .
Ethics and recruitment
All patients will sign the informed consent before inclusion. The study has been approved by the Ethical Research Committees of the China-Japanese Friendship Hospital with identifier 2018-57-K41-1. Any revisions of the study protocol will be submitted to the ethics committee. 
Inclusion criteria
The inclusion criteria are outlined below:
• The diagnostic criteria of COPD reference to Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease 2013 Revision [13] will be adopted as inclusion criteria for this trial ;
• Patients with stable symptoms such as cough, sputum production or breathlessness for • 4 weeks with no AE;
• The risk assessment of AECOPD is high risk in the past 1 year, the number of AE is ≥ 2 times or being hospitalized is ≥ 1 time due to AE ;
• the TCM syndrome pattern of lung qi and spleen qi deficiency, reference to
Guidelines for TCM Diagnosis and Treatment of Chronic Obstructive Pulmonary
Disease 2011 edition [14] ;
• aged between 40 and 80 years;
• with informed signed consent and participate voluntarily in the study.
Exclusion criteria
Exclusion criteria include the following:
• confirmed diagnosis of Pneumonia and/or moderate to severe AECOPD in the past 4 weeks;
• Accepted Pneumonectomy in the past or Lung volume reduction surgery in 12 months before screening;
• Accepted long-term oxygen therapy time > 15h / d or mechanical aerator;
• Patients with a history of asthma, active tuberculosis, lung cancer, bronchiectasis, pulmonary embolism, pulmonary heart disease, interstitial lung disease or other active diseases;
• Patients with lower extremity activity limitation are unable to complete the sixminute walk test;
• Patients were diagnosed with serious hypertension, diabetes, tumors, primary heart, liver, kidney or blood system disease;
• Scr exceeds the upper limit of the reference value by 1.5 times, or AST, ALT ≥ 2 times the upper limit of the reference value;
• Patients with congenital or acquired immunodeficiency disease;
• Patients who are known or suspected of a history of alcohol or drug abuse;
• Patients with confusion, dementia or any kind of mental illness;
• Pregnant or breast-feeding women;
• Allergic to the used medicine;
• Frequent use of glucocorticosteroids orally;
• Patients were enrolled in other clinical trials during the previous three months;
• Researchers believe that who is not appropriate to participate in clinical trials.
Withdrawal, dropout and discontinuation
Participants are free to withdraw at any time during the trial. Participants who wish to withdraw will be offered the option to cease trial medication but continue attending scheduled visits for outcome measurement. Participants who withdraw will be followed to investigate the reason for withdrawal. Participants may be advised to discontinue the treatment if there is a product-related adverse event of a serious nature or if the participant was not compliant with the study requirements.
Discontinuers will not be replaced by new participants. Intention-to-treat analysis will be performed on missing data from discontinuers with the last observation carried forward method.
Sample size
A total of 100 patients will be enrolled into this study with 50 in each group, respectively. The frequency of acute exacerbation of COPD is considered as the primary outcome. According to a previous study [15] [16] , the number of the exacerbation frequency was 1.17 times every year by treatment of conventional medicine, and that was 0.97 times every year by treatment of TCM, and that was 0.68 times every year by treatment of both conventional medicine and TCM. Assume that there would be promotional value only when the exacerbation frequency decreased at least once for one patient every six months. The standard deviation SD value is 1 .25 times per year the two-sided α is 0. 05 and β is 0. 10.
Based on the formula of the comparison between the means of the two samples, the sample size in each group is 40. Considering a 20% dropout rate over the course of the study, 50 patients will be enrolled in each group and the total sample size will be 100.
Randomization and masking
Randomization The block randomization method was used. Select the appropriate length of the segment, and use the SAS9.4 SAS Institute Inc., Cary, NC, USA to generate a randomization sequence for 100 subjects test group, control group according to a 1:1 ratio, and list the treatment allocation corresponding to the serial number 001-100 That is a random coding table .The placebo is made of SHGBZK Chinese medicine 5% and dextrin 95% to insure the mimic appearance, smell, and taste. Both researchers and participants will not know the assignment. The randomization sequence table will be kept in a file. The method, process, group setting, and grouping result of the randomization sequence will be recorded either, so as to be checked when necessary. The information on intervention assignments will be kept in the third consulting center of biomedical statistics. 
Intervention measures
The two groups will receive basic treatment for COPD according to the 2017 GOLD Guidelines for Chronic Obstructive Pulmonary Disease. Patients will stick to the treatment they used to take as much as possible, and will be given present general Patients need to take medication as directed by the doctor from us when it's necessary. The use of glucocorticoids, antibiotics, mucolytic agents and antitussive agents was prohibited during the study except there is AECOPD, and oral or external Chinese medicine preparations with the effect of tonifying spleen and lung were prohibited during the trial period. Patients will be given a daily diary to record their trial medication compliance as well as usage of any other therapies and occurrence of adverse events. Patients will be asked to return their medication bags monthly during the treatment period to enable the counting of left-over capsules as well as part of participant adherence monitoring.
Outcome measure
Primary outcome measure
The frequency of AECOPD is the primary outcome measure. AECOPD is characterized by increased respiratory symptoms, which is beyond daily routine variation, and TCM symptom score TCM symptom of COPD patients at stable stage that diagnosed with syndrome of deficiency of lung qi and spleen qi will be adopted. The TCM symptom score scale is scored from 0 normal to 22 severe . TCM symptom score is shown in table2.
Lung function The indicators of forced vital capacity FVC , forced expiratory volume in 1 s FEV1 , forced expiratory volume in 1 second FEV1% pred and FEV1/FVC ; maximum expiratory mid-flow MMEF and peak expiratory flow FEF will be tested. A positive change from baseline in them will indicate the improvement in lung function.
Dyspnea The Modified Medical Research Council MMRC by the American Thoracic
Society [19] will be assessed to evaluate the level of dyspnea. The MMRC scale is a simple grading system that scored from 0 less severe to 4 severe .
Quality of life The COPD Assessment Test CAT will be adopted. The CAT is the self- The 6-minute walking distance 6MWD This is to evaluate the distance a person can walk on a flat surface in 6 min to assess the exercise capacity.
BODE index will be adopted. BODE stands for Body mass index, airflow Obstruction, Dyspnea and Exercise capacity. Range of BODE scores from 0 to 40. The BODE score was further quartilized as follows: quartile 1 a score of 0 to 2 points , quartile 2 a score of 3 to 4 points , quartile 3 a score of 5 to 6 points , and quartile 4 a score of 7 to 10 points . The higher the level, the worse the patient's condition.
Concomitant medication status Drug therapy that used to treat COPD during the study will be recorded.
Mortality All-cause mortality and COPD mortality will be calculated for the subjects during the study.
Safety
The routine blood, urine, and stool tests, liver and kidney function tests, and an electrocardiogram are performed. Adverse events will be recorded at any time during the treatment period and follow-up period.
Adverse events will be recorded and graded in detail throughout the study, such as possible side effects(no side effects of the herbs have been reported so far). When a severe adverse event occurs, participants will be provided with every necessary treatment, and the event must be reported to the leader of the trial, ethics committees, sponsors and CFDA within 24 hours.
Screening and run-in, baseline, treatment periods and endpoint
The Adverse event, Physical examination, AECOPD situation, MMRC, CAT and TCM symptom score will be recorded at baseline week 0 , in the every 4weeks during the study period. The 6MWD and BODE will be recorded at weeks 0, 4, 12, 24, 32and 52. The lung function will be observed at weeks 0, 24, and 52. Safety will be measured at weeks 0 ,12and 24, except Adverse event and Physical examination.
The schedule of the assessment and interventions is depicted in Figure 2 .
Statistical analysis
All data will be analyzed by an independent statistician using SAS 9.4. For all analyses, P < 0.05 is considered statistically significant. Measurement data will be presented as number of cases, mean, standard deviation, minimum, median, maximum, upper quartile Ql , lower quartile Q3 , 95% confidence interval 95% Cl data. The paired-sample t test or signed rank sum test will be used to compare the difference between the two groups or pretreatment and posttreatment within one group. The analysis of covariance will be used to compare the differences of center effector other confounding factors . According to the previous clinical studies [18] , SHGBZK Chinese medicine has a good clinical effect on improving the effective rate of cough and cough in patients with 100%, improving wheezing efficiency by 85.71%. The total effective rate of SHGBZK is 96.67%, no side effects have been found so far. In our study, we will conduct a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of the Chinese herbal formula SHGBZK Chinese medicine for stable COPD patients that diagnosed with syndrome of deficiency of lung qi and spleen qi. This study may establish a new method for COPD patients at stable stage, and thus differentiation from other drugs used for similar clinical indications in clinical use.
Discussion
In our study, the frequency of acute AECOPD has been chosen as the primary outcome. We also employ validated and objective tools, such as the ACT score and FEV1 as outcome measurements. These measurements improve the reliability and generalizability of the results. Measures will be took to strengthen quality control.
To avoid the bias from the researchers' in the procedure of this study, an investigator separate from all of the clinical researchers will be hired as the contact person who preserve and record the randomization information. Therefore, the clinical researchers do not have any effect on enrollment or randomization.
Meanwhile outcome assessments will be made by an independent clinical statistician blinded to group allocation and uninvolved in providing intervention or management. Otherwise, we built a TCM symptom score 
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